Human DNase I variants
AssigneeGenentech, Inc.
InventorsRobert A. Lazarus, Steven Shak, Jana S. Ulmer
Life of this patent
Estimating the term…
Abstract
The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
Claims22
A human DNase I actin-resistant variant.
A human DNase I actin-resistant variant having an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 by the substitution of one amino acid for another at only a single position within the FIG. 1 sequence.
A human DNase I actin-resistant variant having an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 by the substitution of one amino acid for another at two or more positions within the FIG. 1 sequence.
An isolated nucleic acid encoding a human DNase I actin-resistant variant.
A method for the treatment of a patient having a pulmonary disease or disorder comprising administering to the patient a therapeutically effective amount of an actin-resistant variant of human DNase I.
A pharmaceutical composition comprising an actin-resistant variant of human DNase I and optionally a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.